Roni T. Falk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roni T. Falk has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Ruth M. Pfeiffer
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA
16 shared publications - Gretchen L. Gierach
Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville Maryland USA
9 shared publications Xia Xu
Leidos Biomedical Research, Inc., Frederick, Maryland
9 shared publications- Louise A. Brinton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
8 shared publications - Michael B. Cook
National Cancer Institute, Bethesda, MD, United States
8 shared publications - Jennifer A. Rusiecki
Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, USA
7 shared publications
Latest Publications
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Figure 1. Associations of esophageal adenocarcinoma risk per quantile increase in circulating novel biomarkers in the Department of Defense Serum Repository. Odd ratios (ORs) adjusted for matching variables, marital status and education. (A) displays ORs for the biomarkers in the Inflammation Panel, (B) displays ORs for the biomarkers in the Oncology II Panel, and (C) displays ORs for the biomarkers in the Cardiovascular III Panel.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Figure 1. Associations of esophageal adenocarcinoma risk per quantile increase in circulating novel biomarkers in the Department of Defense Serum Repository. Odd ratios (ORs) adjusted for matching variables, marital status and education. (A) displays ORs for the biomarkers in the Inflammation Panel, (B) displays ORs for the biomarkers in the Oncology II Panel, and (C) displays ORs for the biomarkers in the Cardiovascular III Panel.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 1. Performance characteristics of measurement of 276 inflammation (blue), oncology (red) and cardiovascular (black) biomarkers in the Department of Defense Serum Repository.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 1. Performance characteristics of measurement of 276 inflammation (blue), oncology (red) and cardiovascular (black) biomarkers in the Department of Defense Serum Repository.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 3. Spearman's correlation coefficents among candidate biomarkers in Department of Defense Serum Repository.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 3. Spearman's correlation coefficents among candidate biomarkers in Department of Defense Serum Repository.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Background:We previously identified associations of esophageal adenocarcinoma risk with four inflammation-related candidate biomarkers: TNF receptor 2 (TNFR2), IL17A, VEGFR3, and resistin.Methods:We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case–control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident esophageal adenocarcinoma cases. Controls were matched to cases in a ∼2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and esophageal adenocarcinoma. P values (<0.05) were used to indicate the statistical significance of candidates, and FDR was applied to the additional proteins. ORs from the current analysis and those from previous studies were combined for the candidate markers using fixed-effects meta-analysis.Results:Among the four candidates, the highest category of TNFR2 was associated with significantly increased esophageal adenocarcinoma risk (ORQ4 vs. Q1 = 1.87; 95% confidence interval: 1.02–3.42). In the meta-analysis, associations with esophageal adenocarcinoma were positive for TNFR2 (meta-analyzed ORhighest-vs.-lowest = 2.04; 1.12–2.95) and inverse for IL17A (meta-analyzed ORhighest-vs.-lowest = 0.53; 0.26–0.80). Of the additional 250 proteins, 45 were associated with esophageal adenocarcinoma risk and 6 (monocyte chemotactic protein 3, IL6, TNFR1, hepatocyte growth factor, TFF3, and FURIN) remained significant after FDR correction.Conclusions:We confirmed associations of TNFR2 and IL17A with esophageal adenocarcinoma risk. Additionally, our study expands the range of proteins associated with esophageal adenocarcinoma development.Impact:This is the largest assessment to discover novel associations of inflammation-related proteins with esophageal adenocarcinoma to date.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Background:We previously identified associations of esophageal adenocarcinoma risk with four inflammation-related candidate biomarkers: TNF receptor 2 (TNFR2), IL17A, VEGFR3, and resistin.Methods:We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case–control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident esophageal adenocarcinoma cases. Controls were matched to cases in a ∼2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and esophageal adenocarcinoma. P values (<0.05) were used to indicate the statistical significance of candidates, and FDR was applied to the additional proteins. ORs from the current analysis and those from previous studies were combined for the candidate markers using fixed-effects meta-analysis.Results:Among the four candidates, the highest category of TNFR2 was associated with significantly increased esophageal adenocarcinoma risk (ORQ4 vs. Q1 = 1.87; 95% confidence interval: 1.02–3.42). In the meta-analysis, associations with esophageal adenocarcinoma were positive for TNFR2 (meta-analyzed ORhighest-vs.-lowest = 2.04; 1.12–2.95) and inverse for IL17A (meta-analyzed ORhighest-vs.-lowest = 0.53; 0.26–0.80). Of the additional 250 proteins, 45 were associated with esophageal adenocarcinoma risk and 6 (monocyte chemotactic protein 3, IL6, TNFR1, hepatocyte growth factor, TFF3, and FURIN) remained significant after FDR correction.Conclusions:We confirmed associations of TNFR2 and IL17A with esophageal adenocarcinoma risk. Additionally, our study expands the range of proteins associated with esophageal adenocarcinoma development.Impact:This is the largest assessment to discover novel associations of inflammation-related proteins with esophageal adenocarcinoma to date.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 2. Associations between replicated biomarkers and esophageal adenocarcinoma risk in the Department of Defense Serum Repository, restricting to matched pairs with cases diagnosed ≥5 and ≥10 years after blood draw.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Table 2. Associations between replicated biomarkers and esophageal adenocarcinoma risk in the Department of Defense Serum Repository, restricting to matched pairs with cases diagnosed ≥5 and ≥10 years after blood draw.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Figure 2. Associations of esophageal adenocarcinoma per quantile increase in circulating novel biomarkers in the Department of Defense Serum Repository. Odd Ratios (ORs) adjusted for matching variables, education, marital status, and biomarkers associated with increasing body mass index (EN-RAGE, FGF21, VEGFR3). (A) displays ORs for the biomarkers in the Inflammation Panel, (B) displays ORs for the biomarkers in the Oncology II Panel, and (C) displays ORs for the biomarkers in the Cardiovascular III Panel.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case–Control Study in the Department of Defense Serum Repository
Supplementary Figure 2. Associations of esophageal adenocarcinoma per quantile increase in circulating novel biomarkers in the Department of Defense Serum Repository. Odd Ratios (ORs) adjusted for matching variables, education, marital status, and biomarkers associated with increasing body mass index (EN-RAGE, FGF21, VEGFR3). (A) displays ORs for the biomarkers in the Inflammation Panel, (B) displays ORs for the biomarkers in the Oncology II Panel, and (C) displays ORs for the biomarkers in the Cardiovascular III Panel.
- 13 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case-control Study in the Department of Defense Serum Repository
Background: We previously identified associations of esophageal adenocarcinoma (EA) risk with four inflammation-related candidate biomarkers: TNFR2, IL17A, VEGFR3 and resistin. Methods: We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case-control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident EA cases. Controls were matched to cases in an ~2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and EA. P-values (<0.05) were used to indicate the statistical significance of candidates, and false discovery rate (FDR) was applied to the additional proteins. Odds ratios (ORs) from the current analysis and from previous studies were combined for the candidate markers using fixed effects meta-analysis. Results: Among the four candidates, the highest category of TNFR2 was associated with significantly increased EA risk (ORQ4vsQ1=1.87, 95% confidence interval: 1.02-3.42). In the meta-analysis, associations with EA were positive for TNFR2 (meta-analyzed ORhighest-vs-lowest=2.04, 1.12-2.95) and inverse for IL17A (meta-analyzed ORhighest-vs-lowest=0.53, 0.26-0.80). Of the additional 250 proteins, 45 were associated with EA risk and 6 (MCP3, IL6, TNFR1, HGF, TFF3 and FURIN) remained significant after FDR correction. Conclusions: We confirmed associations of TNFR2 and IL17A with EA risk. Additionally, our study expands the range of proteins associated with EA development. Impact: This is the largest assessment of inflammation-related proteins with EA to date.
- 13 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case-control Study in the Department of Defense Serum Repository
Background: We previously identified associations of esophageal adenocarcinoma (EA) risk with four inflammation-related candidate biomarkers: TNFR2, IL17A, VEGFR3 and resistin. Methods: We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case-control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident EA cases. Controls were matched to cases in an ~2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and EA. P-values (<0.05) were used to indicate the statistical significance of candidates, and false discovery rate (FDR) was applied to the additional proteins. Odds ratios (ORs) from the current analysis and from previous studies were combined for the candidate markers using fixed effects meta-analysis. Results: Among the four candidates, the highest category of TNFR2 was associated with significantly increased EA risk (ORQ4vsQ1=1.87, 95% confidence interval: 1.02-3.42). In the meta-analysis, associations with EA were positive for TNFR2 (meta-analyzed ORhighest-vs-lowest=2.04, 1.12-2.95) and inverse for IL17A (meta-analyzed ORhighest-vs-lowest=0.53, 0.26-0.80). Of the additional 250 proteins, 45 were associated with EA risk and 6 (MCP3, IL6, TNFR1, HGF, TFF3 and FURIN) remained significant after FDR correction. Conclusions: We confirmed associations of TNFR2 and IL17A with EA risk. Additionally, our study expands the range of proteins associated with EA development. Impact: This is the largest assessment of inflammation-related proteins with EA to date.
- Open Access
- 25 January 2023
- Published by Elsevier in Environment International
- Vol. 172, 107777
Glyphosate in house dust and risk of childhood acute lymphoblastic leukemia in California
- 25 January 2023
- Published by Elsevier in Environment International
- Vol. 172, 107777
Open AccessGlyphosate in house dust and risk of childhood acute lymphoblastic leukemia in California
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2385
Abstract 2385: A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary cancer
Background: Laboratory and emerging epidemiologic data suggest that bile acids (BAs), major regulators of the gut microbiota, play an important role in liver disease and cancer etiology. However, few epidemiologic studies have comprehensively examined associations between BAs and either liver endpoints or biliary cancer. Methods: In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, we designed 1:1 matched nested case-control studies of primary liver cancer (n=247 cases), fatal liver disease (n=261 cases), and primary biliary cancer (n=92 cases). Using baseline serum collected ≤30 years prior to diagnosis or death, we measured concentrations of 15 BAs with liquid chromatography tandem mass spectrometry. We used multivariable conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) between BAs and each endpoint, accounting for multiple comparisons. Results: Comparing the highest to the lowest quartile, ten BAs were positively associated with liver cancer risk, including taurocholic (OR =4.70, 95% CI=2.51-8.78; Q-trendCitation Format: Zeinab Farhat, Neal D. Freedman, Joshua N. Sampson, Roni T. Falk, Jill Koshiol, Stephanie J. Weinstein, Demetrius Albanes, Rashmi Sinha, Erikka Loftfield. A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2385.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2385
Open AccessAbstract 2385: A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary cancer
Background: Laboratory and emerging epidemiologic data suggest that bile acids (BAs), major regulators of the gut microbiota, play an important role in liver disease and cancer etiology. However, few epidemiologic studies have comprehensively examined associations between BAs and either liver endpoints or biliary cancer. Methods: In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, we designed 1:1 matched nested case-control studies of primary liver cancer (n=247 cases), fatal liver disease (n=261 cases), and primary biliary cancer (n=92 cases). Using baseline serum collected ≤30 years prior to diagnosis or death, we measured concentrations of 15 BAs with liquid chromatography tandem mass spectrometry. We used multivariable conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) between BAs and each endpoint, accounting for multiple comparisons. Results: Comparing the highest to the lowest quartile, ten BAs were positively associated with liver cancer risk, including taurocholic (OR =4.70, 95% CI=2.51-8.78; Q-trendCitation Format: Zeinab Farhat, Neal D. Freedman, Joshua N. Sampson, Roni T. Falk, Jill Koshiol, Stephanie J. Weinstein, Demetrius Albanes, Rashmi Sinha, Erikka Loftfield. A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2385.
- Open Access
- 30 March 2022
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 6 (3)
Prospective Associations of Circulating Bile Acids and Short-Chain Fatty Acids With Incident Colorectal Cancer
Human studies investigating the prospective relationship between microbial metabolites and colorectal cancer (CRC) risk are lacking. We tested whether higher serum bile acids (BAs) and lower short-chain fatty acids (SCFAs) were associated with CRC risk. In baseline serum collected more than 30 years before a CRC diagnosis, we quantified concentrations of 15 BAs and 6 SCFAs using targeted liquid chromatography with tandem mass spectrometry assays in 1:1 matched cases and controls from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (men: n = 262 cases; women: n = 233 cases) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (men: n = 598 cases). We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for BA and SCFA quartiles and summary measures with CRC overall and by anatomic location using multivariable conditional logistic regression models. PLCO analyses were stratified by sex. All statistical tests were 2-sided. In PLCO women, 7 BAs were strongly associated with increased CRC risk, including the secondary BAs, deoxycholic (ORQ4 v Q1 = 2.85, 95% CI = 1.45 to 5.60, Qtrend = 0.011), glycodeoxycholic (OR Q4 v Q1 = 3.45, 95% CI = 1.79 to 6.64, Qtrend = 0.006), taurodeoxycholic (OR Q4 v Q1 = 2.36, 95% CI = 1.22 to 4.55, Qtrend = 0.023), and glycolithocholic acid (ORQ4 v Q1 = 2.71, 95% CI = 1.41 to 5.22, Qtrend = 0.015). Women in the highest compared with lowest quartile of total SCFAs had a 45% lower risk of CRC (OR = 0.55, 95% CI = 0.31 to 0.98, Ptrend = .03). Associations for total BAs and SCFAs were strongest among women with proximal colon cancer. No statistically significant associations were observed for BA or SCFA measures among men. Serum concentrations of BAs, particularly downstream microbial metabolites of cholic acid, were strongly associated with increased risk of CRC among women.
- 30 March 2022
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 6 (3)
Open AccessProspective Associations of Circulating Bile Acids and Short-Chain Fatty Acids With Incident Colorectal Cancer
Human studies investigating the prospective relationship between microbial metabolites and colorectal cancer (CRC) risk are lacking. We tested whether higher serum bile acids (BAs) and lower short-chain fatty acids (SCFAs) were associated with CRC risk. In baseline serum collected more than 30 years before a CRC diagnosis, we quantified concentrations of 15 BAs and 6 SCFAs using targeted liquid chromatography with tandem mass spectrometry assays in 1:1 matched cases and controls from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (men: n = 262 cases; women: n = 233 cases) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (men: n = 598 cases). We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for BA and SCFA quartiles and summary measures with CRC overall and by anatomic location using multivariable conditional logistic regression models. PLCO analyses were stratified by sex. All statistical tests were 2-sided. In PLCO women, 7 BAs were strongly associated with increased CRC risk, including the secondary BAs, deoxycholic (ORQ4 v Q1 = 2.85, 95% CI = 1.45 to 5.60, Qtrend = 0.011), glycodeoxycholic (OR Q4 v Q1 = 3.45, 95% CI = 1.79 to 6.64, Qtrend = 0.006), taurodeoxycholic (OR Q4 v Q1 = 2.36, 95% CI = 1.22 to 4.55, Qtrend = 0.023), and glycolithocholic acid (ORQ4 v Q1 = 2.71, 95% CI = 1.41 to 5.22, Qtrend = 0.015). Women in the highest compared with lowest quartile of total SCFAs had a 45% lower risk of CRC (OR = 0.55, 95% CI = 0.31 to 0.98, Ptrend = .03). Associations for total BAs and SCFAs were strongest among women with proximal colon cancer. No statistically significant associations were observed for BA or SCFA measures among men. Serum concentrations of BAs, particularly downstream microbial metabolites of cholic acid, were strongly associated with increased risk of CRC among women.